Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.37 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 8/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23725133 | 0.85 | KDR (0.42) | KDRHDAC8FGFR3SMN1; SMN2 | |
| SCHEMBL23725833 | 0.83 | CD274 (0.44) | PDCD1CD274 | |
| SCHEMBL23726939 | 0.82 | KDR (0.37) | KDRHDAC8FGFR3 | |
| SCHEMBL23724463 | 0.82 | CD274 (0.47) | PDCD1CD274 | |
| SCHEMBL23726025 | 0.81 | CD274 (0.38) | KDRFGFR3PDCD1CD274 | |
| SCHEMBL23726936 | 0.78 | KDR (0.40) | KDRHDAC8FGFR3SMN1; SMN2 | |
| SCHEMBL23726576 | 0.77 | KDR (0.43) | KDRHDAC8FGFR3SMN1; SMN2 | |
| SCHEMBL30431911 | 0.77 | SMN1; SMN2 (0.47) | HTTLMNASMN1; SMN2 | |
| SCHEMBL23725758 | 0.74 | KDR (0.44) | KDRFGFR3HTTLMNASMN1; SMN2 | |
| SCHEMBL30433252 | 0.73 | SSTR4 (0.42) | KDRFGFR3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4100381-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158481-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | KDR 3652/4885HDAC8 1908/4885USP28 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.